Vinod Jona, MD
Pulmonary Disease · Florence, SCNPI 1154361723
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,800 of the $78,182 with a category attached, or 73.9%. GSK accounts for 76.0% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2021 at $25,566 and has fallen 93.0% since, to $1,801 in 2025. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 557 payments — averaging $140.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$59K
- Intuitive Surgical$7K
- Sanofi$3K
- AstraZeneca$2K
- Veran Medical Technologies, Inc.$959
- Olympus Corporation Of The Americas$910
- plus $5K from 45 others
What the payments were for
- Consulting fees$2,2353%
- Speaking & faculty fees$57,80074%
- Travel & lodging$4,9356%
- Food & beverage$10,11913%
- Education$3,0934%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$44,901
- ION$3,000
- Da Vinci Surgical System$2,962
- DUPIXENT$2,612
- Spin$950
- Olympus Bronchoscopes$806
- Olympus Capital Accessories$806
- Olympus Respiratory Accessories$806
- AIRSUPRA$343
- BREZTRI$343
- TEZSPIRE$343
- FASENRA$343
- ALIYA SYSTEM$117
- TRUFREEZE$116
- SYMBICORT$108
- INVOKANA$105
How this compares
$78,182 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 35 | $2,165,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 865 | $652,336 |
| OpsumitMacitentan | 37 | $445,745 |
| Sodium Oxybate | 25 | $369,933 |
| OfevNintedanib Esylate | 25 | $326,394 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 341 | $237,937 |
| TezspireTezepelumab-Ekko | 38 | $188,952 |
| Dupixent SyringeDupilumab | 46 | $165,915 |
| Dupixent PenDupilumab | 40 | $164,231 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 315 | $162,199 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 162 | $91,999 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $54,775 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $27,199 |
| Spiriva RespimatTiotropium Bromide | 29 | $20,908 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 676 | $19,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $332 | $2,165,04335 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $59,434 | $879,1991,310 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $354 | $466,500266 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $1,950 | $447,147448 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $255 | $445,74537 claims |
| PfizerEliquis | $25 | $16,61126 claims |
| Johnson & JohnsonXarelto | $148 | $9,84216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Florence
- Lorie LoremanFlorence$62K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
- Jake KriegmdColumbia$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.